BRCA1 and cancer: Notably, the potency of various clinical PARPis in trapping PARP1/2 correlates with their efficacy in killing BRCA1/2-deficient cancer cells, suggesting that PARPi induces DNA damage by trapping PARP1/2 on DNA (Figure 1B).